PMID- 19887019
OWN - NLM
STAT- MEDLINE
DCOM- 20100714
LR  - 20161020
IS  - 1469-5111 (Electronic)
IS  - 1461-1457 (Linking)
VI  - 13
IP  - 4
DP  - 2010 May
TI  - A randomized, double-blind, placebo-controlled comparison study of sarcosine 
      (N-methylglycine) and D-serine add-on treatment for schizophrenia.
PG  - 451-60
LID - 10.1017/S1461145709990939 [doi]
AB  - Recent evidence indicates that enhancing N-methyl-D-aspartate (NMDA) 
      neurotransmission with the treatment of NMDA/glycine site agonists, such as 
      D-serine, or a glycine transporter-1 (GlyT-1) antagonist, N-methylglycine 
      (sarcosine), can improve symptoms of schizophrenia. To compare these two novel 
      approaches, 60 patients with chronic schizophrenia were enrolled into a 6-wk 
      double-blind, placebo-controlled trial of add-on treatments at the reported 
      effective dosages (2 g/d). Clinical assessments were conducted every other week. 
      Treatment group x treatment duration interaction analysis by multiple linear 
      regression showed that sarcosine was superior to placebo at all four outcome 
      measures of Positive and Negative Syndrome Scale (PANSS) total (p=0.005), Scale 
      for the Assessment of Negative Symptoms (SANS) (p=0.021), Quality of Life (QOL) 
      (p=0.025), and Global Assessment of Functioning (GAF) (p=0.042). However, 
      d-serine did not differ significantly from placebo in any measure. Sarcosine 
      treatment was better than d-serine in effect sizes for all outcome measures. 
      Sarcosine also surpassed placebo in most of the measures of five PANSS factors 
      and five SANS subscales. All treatments were well tolerated. These findings 
      suggest that the GlyT-1 inhibitor is more efficacious than the NMDA/glycine site 
      agonist in treatment for schizophrenia, including life quality and global 
      function, at the dosages tested.
FAU - Lane, Hsien-Yuan
AU  - Lane HY
AD  - Department of Psychiatry, China Medical University and Hospital, Taichung, 
      Taiwan.
FAU - Lin, Ching-Hua
AU  - Lin CH
FAU - Huang, Yu-Jhen
AU  - Huang YJ
FAU - Liao, Chun-Hui
AU  - Liao CH
FAU - Chang, Yue-Cune
AU  - Chang YC
FAU - Tsai, Guochuan E
AU  - Tsai GE
LA  - eng
SI  - ClinicalTrials.gov/NCT00491569
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20091104
PL  - England
TA  - Int J Neuropsychopharmacol
JT  - The international journal of neuropsychopharmacology
JID - 9815893
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Placebos)
RN  - 452VLY9402 (Serine)
RN  - Z711V88R5F (Sarcosine)
SB  - IM
MH  - Activities of Daily Living
MH  - Adult
MH  - Antipsychotic Agents/*administration & dosage
MH  - Chronic Disease
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Placebos
MH  - Quality of Life
MH  - Sarcosine/*administration & dosage
MH  - Schizophrenia/diagnosis/*drug therapy
MH  - *Schizophrenic Psychology
MH  - Serine/*administration & dosage
MH  - Stereoisomerism
EDAT- 2009/11/06 06:00
MHDA- 2010/07/16 06:00
CRDT- 2009/11/06 06:00
PHST- 2009/11/06 06:00 [entrez]
PHST- 2009/11/06 06:00 [pubmed]
PHST- 2010/07/16 06:00 [medline]
AID - S1461145709990939 [pii]
AID - 10.1017/S1461145709990939 [doi]
PST - ppublish
SO  - Int J Neuropsychopharmacol. 2010 May;13(4):451-60. doi: 
      10.1017/S1461145709990939. Epub 2009 Nov 4.